全文获取类型
收费全文 | 233111篇 |
免费 | 20173篇 |
国内免费 | 8537篇 |
专业分类
耳鼻咽喉 | 3157篇 |
儿科学 | 3335篇 |
妇产科学 | 3996篇 |
基础医学 | 28030篇 |
口腔科学 | 3634篇 |
临床医学 | 23452篇 |
内科学 | 25589篇 |
皮肤病学 | 1932篇 |
神经病学 | 8082篇 |
特种医学 | 8454篇 |
外国民族医学 | 116篇 |
外科学 | 30077篇 |
综合类 | 37584篇 |
现状与发展 | 14篇 |
一般理论 | 25篇 |
预防医学 | 12847篇 |
眼科学 | 4474篇 |
药学 | 19886篇 |
37篇 | |
中国医学 | 8258篇 |
肿瘤学 | 38842篇 |
出版年
2024年 | 431篇 |
2023年 | 2714篇 |
2022年 | 5494篇 |
2021年 | 7909篇 |
2020年 | 7195篇 |
2019年 | 7072篇 |
2018年 | 6771篇 |
2017年 | 7026篇 |
2016年 | 7757篇 |
2015年 | 7623篇 |
2014年 | 12779篇 |
2013年 | 13236篇 |
2012年 | 12658篇 |
2011年 | 14335篇 |
2010年 | 12459篇 |
2009年 | 12234篇 |
2008年 | 12050篇 |
2007年 | 13440篇 |
2006年 | 12386篇 |
2005年 | 11960篇 |
2004年 | 10177篇 |
2003年 | 8951篇 |
2002年 | 7017篇 |
2001年 | 6886篇 |
2000年 | 5656篇 |
1999年 | 4927篇 |
1998年 | 3635篇 |
1997年 | 3249篇 |
1996年 | 2949篇 |
1995年 | 2779篇 |
1994年 | 2423篇 |
1993年 | 2039篇 |
1992年 | 1747篇 |
1991年 | 1504篇 |
1990年 | 1270篇 |
1989年 | 1188篇 |
1988年 | 1141篇 |
1987年 | 878篇 |
1986年 | 679篇 |
1985年 | 768篇 |
1984年 | 724篇 |
1983年 | 466篇 |
1982年 | 584篇 |
1981年 | 486篇 |
1980年 | 420篇 |
1979年 | 333篇 |
1978年 | 277篇 |
1977年 | 228篇 |
1976年 | 250篇 |
1975年 | 160篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
82.
83.
目的 前瞻性评估T1~T2期乳腺癌保乳术后化疗后程大分割放疗的不良反应和耐受性,以及在缩短治疗时间、减轻患者经济负担等方面的价值。方法 共入组20例T1~T2期乳腺癌保乳术后患者,所有患者于末次多西他赛化疗前开始大分割放疗。观察急性放射反应、治疗完成率及无病生存率、住院时间及住院费用等。结果 治疗完成率100%。主要不良反应为血液学毒性(白细胞减少)及皮肤反应,患者均可耐受。中位随访时间为30.1个月,随访率100%。美容效果良好率100%。平均总治疗时间为4周,总住院治疗费用节省约1万元。21个月无病生存率为100%。结论 T1~T2期乳腺癌保乳术后可耐受同步大分割放化疗,局部控制好,美容效果佳,且具有较高的卫生经济学价值。 相似文献
84.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献85.
86.
目的探讨喉癌患者血小板表面血小板膜糖蛋白Ⅱb/Ⅲa纤维蛋白原受体(PAC-1)、血小板P-选择素(CD62P)阳性表达率以及与患者临床病理特征和复发的关系。方法选取2014年1月~2015年12月间在我院耳鼻喉科手术治疗的116例喉癌患者,随访≥2年,并选取同期在我院体检的健康人群60例为对照组,采用流式细胞仪检测法检测外周血PAC-1和CD62P阳性率,并分析与临床病理特征、复发的关系。结果喉癌患者PAC-1和CD62P阳性表达率分别为(17.82±1.76)%和(22.87±3.13)%,明显高于健康人群(P<0.05);而且在喉癌患者PAC-1表达和CD62P表达呈正相关性(r=0.238,P<0.05)。T3-T4分期或N2-N3分期患者PAC-1和CD62P阳性表达率高于T1-T2分期或N0-N1分期患者(P<0.05)。另外远处转移组PAC-1和CD62P阳性表达率高于未发生转移组(P<0.05);随访期间有24例患者复发,复发率为20.69%。复发喉癌患者PAC-1、CD62P阳性表达率分别为(17.02±0.85)%和(21.84±1.17)%,明显高于未复发的喉癌患者(P<0.05)。经Logistics回归分析,PAC-1和CD62P是喉癌患者复发的独立危险因素(P<0.05)。结论PAC-1和CD62P阳性表达率与喉癌患者T分期、淋巴结转移和远处转移密切相关,同时可作为喉癌局部复发、区域淋巴结转移、远处转移的预测指标。 相似文献
87.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2020,32(5):303-315
The lung is the preferred site of metastasis from soft tissue sarcoma (STS). This systematic review aims to evaluate the outcomes of stereotactic body radiotherapy (SBRT) and metastasectomy (MTS) for the treatment of lung metastases from STS. A systematic review was carried out according to the PRISMA protocol. PubMed, Medline, EMBASE, Cochrane Library, Ovid and Web of Knowledge databases were searched for English-language articles to December 2018 using a predefined strategy. Retrieved studies were independently screened and rated for relevance. Data were extracted by two researchers. In total, there were 1306 patients with STS: 1104 underwent MTS and 202 had SBRT. The mean age ranged from 40 to 55.8 years in the MTS group and from 47.9 to 64 years in the SBRT group. The cumulative death rate was 72% (95% confidence interval 59–85%) in the MTS group and 56% (38–74%) in the SBRT group. The cumulative mean overall survival time was 46.7 months (36.4–57.0%) in the MTS group and 47.6 months (33.7–61.5%) in the SBRT group. The cumulative rate of patients alive with disease was 5% (2–9%) in the MTS group and 15% (6–36%) in the SBRT group. Finally, the cumulative rate of patients alive without disease in the two groups was 19% (9–29%) and 20% (10–50%), respectively. Our study showed that local treatment of pulmonary metastases from STS with SBRT, compared with surgery, was associated with a lower cumulative overall death rate and similar overall survival time and survival rates without disease. By contrast, SBRT was associated with a higher survival rate with disease than MTS. Large randomised trials are necessary to confirm these findings and to establish whether SBRT may be a reliable option for early stage disease. 相似文献
88.
Walid K. Abu Saleh Phillip Mason Odeaa Al Jabbari Hany Samir Brian A. Bruckner 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(6):569-571
The Impella 5.0, a percutaneously inserted left ventricular assist device, has been used to support patients who have severe heart failure or who are undergoing high-risk percutaneous coronary intervention. We report our surgical placement of the Impella 5.0, through a graft sewn to the aorta, to unload the left ventricle of a 59-year-old man who was undergoing venoarterial extracorporeal membrane oxygenation for postcardiotomy shock. The patient underwent successful placement of a long-term left ventricular assist device before his discharge from the hospital. The versatility of the Impella 5.0 is exemplified in this patient who was successfully bridged to long-term support. 相似文献
89.
André Ricardo Adriano Tiago Silveira Lima Maxime Battistella Martine Bagot 《Anais brasileiros de dermatologia》2015,90(6):892-895
Granulomatous slack skin is an indolent T-cell lymphoma, considered to be a
variant of mycosis fungoides. Clinically it is characterized by areas of
redundant skin, wrinkled, inelastic, with variable erythema and
infiltration besides a poikilodermic surface. A differential diagnosis
unknown to most dermatologists is the giant cell tumor of soft tissue,
which is an extremely rare low-grade sarcoma. The authors report a patient
who had undergone extensive surgery because of a primary diagnosis of giant
cell tumor of soft tissue, but which proved to be granulomatous slack skin
after a second interventional procedure with confirmatory
histopathology. 相似文献
90.